Therapie der eosinophilen Ösophagitis - Fortschritte und Perspektiven

Zusammenfassung

In jüngster Zeit wurden in der Therapie der eosinophilen Ösophagitis (EoE) und insbesondere im Bereich der topischen Corticosteroide erhebliche Fortschritte erreicht. Neue EoE-spezifische Darreichungsformen wurden entwickelt und haben in Form der orodispersiblen Budesonid-Tablette zu der ersten in Deutschland und anderen europäischen und außereuropäischen Ländern zugelassenen Therapie der EoE bei Erwachsenen geführt. In den USA steht eine EoE-spezifische orale Budesonid-Suspension kurz vor der Zulassung. Dagegen bleibt die wissenschaftliche Datenlage zur Wirksamkeit von Protonenpumpeninhibtoren weiterhin limitiert. Auch im Bereich der Biologika konnten nach langer Zeit Substanzen identifiziert werden, die erstmals in Phase 2 sehr vielversprechende Ergebnisse gezeigt haben und sich derzeit in klinischen Prüfungen der Phase 3 befinden. In diesem Artikel sollen die aktuellen Fortschritte und Perspektiven in der Therapie der EoE dargestellt und diskutiert werden.

Abstract

In recent years significant progress has been made in the treatment of eosinophilic esophagitis (EoE), especially in the area of topical corticosteroids. Novel EoE-specific formulations have been developed and first approvals have been obtained for induction and maintenance of remission in adult EoE patients with the orodispersible budesonide tablet in Germany and other European and non-EU countries. A novel budesonide oral suspension is currently under priority review by the FDA for first approval in the U.S. In contrast, the scientific evidence on the efficacy of proton pump inhibitors remains limited. Moreover, new biologicals have been identified which showed promising results in phase 2 trials and are now being studied in phase 3. This article aims to summarize and discuss recent advances and perspectives in the treatment of EoE.

Schlüsselwörter

Eosinophile Ösophagitis - Budesonid - Fluticason - Protonenpumpeninhibitor - Biologika

Keywords

eosinophilic esophagitis - topical corticosteroids - budesonide - fluticasone - proton pump inhibitor - elimination diet - biological

Publication History

Received: 07 February 2021

Accepted: 07 March 2021

Article published online:
04 May 2023

• Literatur

• 1 Lucendo AJ, Molina-Infante J, Arias Á. et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterol J 2017; 5: 335-358 DOI: 10.1177/2050640616689525. (PMID: 28507746)
• 2 Navarro P, Arias A, Aria-Gonzalez L. et al. Systematic review with metaanalysis: the growing incidence and prevalence of eosinophilic oesophagitis in children and adults in population‐based studies. Aliment Pharmacol Ther 2019; 49: 1116-1125
• 3 Sengupta N, Tapper EB, Corban C. et al. The clinical predictors of aetiology and complications among 173 patients presenting to the Emergency Department with oesophageal food bolus impaction from 2004–2014. Aliment Pharmacol Ther 2015; 42: 91-98
• 4 Lenz CJ, Leggett C, Katzka DA. et al. Food impaction: etiology over 35 years and association with eosinophilic esophagitis. Dis Esophagus 2019; 32: doz010 DOI: 10.1093/dote/doz010. (PMID: 30847465)
• 5 Dellon ES, Hirano I. Epidemiology and Natural History of Eosinophilic Esophagitis. Gastroenterology 2018; 154: 319-332 DOI: 10.1053/j.gastro.2017.06.067. (PMID: 28774845)
• 6 Straumann A, Spichtin HP, Grize L. et al. Natural History of Primary Eosinophilic Esophagitis: A Follow-up of 30 Adult Patients for Up to 11.5 Years. Gastroenterology 2003; 125: 1660-1669 DOI: 10.1053/j.gastro.2003.09.024. (PMID: 14724818)
• 7 Schoepfer AM, Safroneeva E, Bussmann C. et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. Gastroenterology 2013; 145: 1230-1236 DOI: 10.1053/j.gastro.2013.08.015. (PMID: 23954315)
• 8 Warners MJ, Oude Nijhuis RAB, de Wijkerslooth LRH. et al. The natural course of eosinophilic esophagitis and long-term consequences of undiagnosed disease in a large cohort. Am J Gastroenterol 2018; 113: 836-844
• 9 Shaheen NJ, Mukkada V, Eichinger CS. et al. Natural history of eosinophilic esophagitis: a systematic review of epidemiology and disease course. Dis Esophagus 2018; 31 DOI: 10.1093/dote/doy015. (PMID: 29617744)
• 10 Lucendo AJ, Arias-Gonzalez L, Molina-Infante J. et al. Systematic review: health-related quality of life in children and adults with eosinophilic oesophagitis-instruments for measurement and determinant factors. Aliment Pharmacol Ther 2017; 46: 401-409 DOI: 10.1111/apt.14194. (PMID: 28639700)
• 11 Alexander R, Alexander JA, Ravi K. et al. Measurement of Observed Eating Behaviors in Patients With Active and Inactive Eosinophilic Esophagitis. Clinical Gastroenterology and Hepatology 2019; 17: 2371-2373 DOI: 10.1016/j.cgh.2018.12.011. (PMID: 30557737)
• 12 Hirano I, Chan ES, Rank MA. et al. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis. Gastroenterology 2020; 158: 1776-1786 DOI: 10.1053/j.gastro.2020.02.038. (PMID: 32359562)
• 13 O'Shea KM, Aceves SS, Dellon ES. et al. Pathophysiology of Eosinophilic Esophagitis. Gastroenterology 2018; 154: 333-345 DOI: 10.1053/j.gastro.2017.06.065. (PMID: 28757265)
• 14 Dellon ES, Gupta SK. A Conceptual Approach to Understanding Treatment Response in Eosinophilic Esophagitis. Clin Gastroenterol Hepatol 2019; 17: 2149-2160 DOI: 10.1016/j.cgh.2019.01.030. (PMID: 30710696)
• 15 Miehlke S, Schlag C, Storr M. et al. Eosinophilic Esophagitis Update: New Guidelines of the European Study Group EUREOS. Z Gastroenterol 2018; 56: 139-150 DOI: 10.1055/s-0043-121349. (PMID: 29121691)
• 16 Miehlke S, von Arnim U, Schlag C. et al. Clinical Management of Eosinophilic Esophagitis- a nation-wide survey among gastroenterologists in Germany. Z Gastroenterol 2019; 57: 745-752
• 17 Nennstiel S, Schlag C. Treatment of eosinophlic esophagitis with swallowed topical corticosteroids. World J Gastroenterol 2020; 26: 5395-5407 DOI: 10.3748/wjg.v26.i36.5395. (PMID: 33024392)
• 18 De Heer J, Miehlke S, Rösch T. et al. Histologic and Clinical Effects of Different Topical Corticosteroids for Eosinophilic Esophagitis: Lessons from an Updated Meta-Analysis of Placebo-Controlled Randomized Trial. Digestion 2020; 1-9 DOI: 10.1159/000507571.
• 19 Gupta SK, Vitanza JM, Collins MH. Efficacy and Safety of Oral Budesonide Suspension in Pediatric Patients With Eosinophilic Esophagitis. Clin Gastroenterol Hepatol 2015; 13: 66-76 DOI: 10.1016/j.cgh.2014.05.021. (PMID: 24907502)
• 20 Miehlke S, Hruz P, Vieth M. et al. A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis. Gut 2016; 65: 390-399 DOI: 10.1136/gutjnl-2014-308815. (PMID: 25792708)
• 21 Dellon ES, Katzka DA, Collins MH. et al. Budesonide oral suspension improves symptomatic, endoscopic, and histologic parameters compared with placebo in patients with eosinophilic esophagitis. Gastroenterology 2017; 152: 776-786 DOI: 10.1053/j.gastro.2016.11.021. (PMID: 27889574)
• 22 Lucendo AJ, Miehlke S, Schlag C. et al. Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-controlled Trial. Gastroenterology 2019; 157: 74-86 DOI: 10.1053/j.gastro.2019.03.025. (PMID: 30922997)
• 23 Hirano I, Mukkada VA, Falk GW. et al. Efficacy of budesonide oral suspension for eosinophilic esophagitis in adolescents and adults: results from a phase 3 randomized, placebo-controlled tral. Am J Gastroenterol 2019; 114: S205-S206
• 24 Hirano I, Safroneeva E, Roumet MC. et al. Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis. Aliment Pharmacol Ther 2020; 51: 750-775 DOI: 10.1111/apt.15670. (PMID: 32149424)
• 25 Schlag C, Dellon ES, Lucendo AJ. et al. Wirksamkeit und Sicherheit der Langzeittherapie der Eosinophilen Ösophagitis mit einer neuen sich im Mund auflösenden Fluticason-Tablette (APT-1011): Ergebnisse einer internationalen randomisierten doppel-blinden Placebo-kontrollierten Phase 2b-Studie. Z Gastroenterol 2020; 58: e129 DOI: 10.1055/s-0040-1716079.
• 26 Schlag C, Miehlke S, Lucendo A. et al. Efficacy of budesonide orodispersible tablets for induction of remission in patients with active eosinophilic esophagitis: Results from the 6-weeks open-label treatment phase of EOS-2 trial. Gastroenterology 2019; 156: S71 DOI: 10.1053/j.gastro.2019.03.025.
• 27 Dellon ES, Katzka DA, Collins MH. et al. Safety and Efficacy of Budesonide Oral Suspension Maintenance Therapy in Patients With Eosinophilic Esophagitis. Clin Gastroenterol Hepatol 2019; 17: 666-673 DOI: 10.1016/j.cgh.2018.05.051. (PMID: 29902649)
• 28 Straumann A, Lucendo AJ, Miehlke S. et al. Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis. Gastroenterology 2020; DOI: 10.1053/j.gastro.2020.07.039.
• 29 Miehlke S, Lucendo AJ, Straumann A. et al. Orodispersible budesonide tablets for the treatment of eosinophilic esophagitis – a review of the latest evidence. Ther Adv Gastroenterol 2020; 13: 1-15 DOI: 10.1177/1756284820927282. (PMID: 32565912)
• 30 Rokkas T, Niv Y, Malfertheiner P. A Network Meta-Analysis of Randomized Controlled Trials on the Treatment of Eosinophilic Esophagitis in Adults and Children. J Clin Gastroenterol 2020; DOI: 10.1097/MCG.0000000000001356.
• 31 Lucendo AJ, Arias A, Molina-Infante J. Efficacy of Proton Pump Inhibitor Drugs for Inducing Clinical and Histologic Remission in Patients With Symptomatic Esophageal Eosinophilia: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol 2016; 14: 13-22 DOI: 10.1016/j.cgh.2015.07.041. (PMID: 26247167)
• 32 Gómez-Torrijos E, García-Rodríguez R, Castro-Jiménez A. et al. The efficacy of step-down therapy in adult patients with proton pump inhibitorresponsive oesophageal eosinophilia. Aliment Pharmacol Ther 2016; 43: 534-540 DOI: 10.1111/apt.13496. (PMID: 26662868)
• 33 Laserna-Mendieta EJ, Casabona S, Guagnozzi D. et al. Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry. Aliment Pharmacol Ther 2020; 52: 798-807 DOI: 10.1111/apt.15957. (PMID: 32677040)
• 34 Miehlke S, von Arnim U, Attwood S. Letter: PPI in EoE: more questions than answers. Aliment Pharmacol Ther 2021; 53: 364-365
• 35 Alexander R, Alexander JA, Akambase J. et al. Proton Pump Inhibitor Therapy in Eosinophilic Esophagitis: Predictors of Nonresponse. Dig Dis Sci 2020; DOI: 10.1007/s10620-020-06633-4. (PMID: 32995996)
• 36 Vaezi MF, Yang YX, Howden CW. Complications of Proton Pump Inhibitor Therapy. Gastroenterology 2017; 153: 35-48 DOI: 10.1053/j.gastro.2017.04.047. (PMID: 28528705)
• 37 Daniell HW. Acid suppressing therapy as a risk factor for Candida esophagitis. Dis Esophagus 2016; 29: 479-83 DOI: 10.1111/dote.12354. (PMID: 25833302)
• 38 Arias A, Gonzales-Cervera J, Tenias TM. et al. Efficacy of dietary interventions for inducing histologic remission in patients with eosinophilic esophagitis: a systematic review and meta-analysis. Gastroenterology 2014; 146: 1639-1648
• 39 Gonsalves N, Yang GY, Doerfler B. et al. Elimination diet effectively treats eosinophilic esophagitis in adults; food reintroduction identifies causative factors. Gastroenterology 2012; 142: 1451-1459 DOI: 10.1053/j.gastro.2012.03.001. (PMID: 22391333)
• 40 Molina-Infante J, Arias Á, Alcedo J. et al. Step-up empiric elimination diet for pediatric and adult eosinophilic esophagitis: The 2–4-6 study. J Allergy Clin Immunol 2018; 141: 1365-1372 DOI: 10.1016/j.jaci.2017.08.038. (PMID: 29074457)
• 41 Molina-Infante J, Lucendo AJ. Dietary therapy for eosinophilic esophagitis. J Allergy Clin Immunol 2018; 142: 41-47 DOI: 10.1016/j.jaci.2018.02.028. (PMID: 29522850)
• 42 Reed CC, Fan C, Koutlas NT. et al. Food elimination diets are effective for long-term treatment of adults with eosinophilic oesophagitis. Aliment Pharmacol Ther 2017; 46: 836-844 DOI: 10.1111/apt.14290. (PMID: 28877359)
• 43 Schaefer ET, Fitzgerald JF, Molleston JP. et al. Comparison of Oral Prednisone and Topical Fluticasone in the Treatment of Eosinophilic Esophagitis: A Randomized Trial in Children. Clin Gastroenterol Hepatol 2008; 6: 165-173 DOI: 10.1016/j.cgh.2007.11.008. (PMID: 18237866)
• 44 Lucendo AJ, De Rezende LC, Jiménez-Contreras S. et al. Montelukast was inefficient in maintaining steroid-induced remission in adult eosinophilic esophagitis. Dig Dis Sci 2011; 56: 3551-3558 DOI: 10.1007/s10620-011-1775-y. (PMID: 21674173)
• 45 Straumann A, Hoesli S, Bussmann C. et al. Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis. Allergy 2013; 68: 375-385 DOI: 10.1111/all.12096. (PMID: 23379537)
• 46 Moawad FJ, Molina-Infante J, Lucendo AJ. et al. Systematic review with meta-analysis: endoscopic dilation is highly effective and safe in children and adults with eosinophilic oesophagitis. Aliment Pharmacol Ther 2017; 46: 96-105 DOI: 10.1111/apt.14123. (PMID: 28513085)
• 47 Dougherty M, Runge TM, Eluri S. et al. Esophageal dilation with either bougie or balloon technique as a treatment for eosinophilic esophagitis: a systematic review and meta-analysis. Gastrointest Endosc 2017; 86: 581-591 DOI: 10.1016/j.gie.2017.04.028. (PMID: 28461094)
• 48 de Rooij WE, Dellon ES, Parker CE. et al. Pharmacotherapies for the Treatment of Eosinophilic Esophagitis: State of the Art Review. Drugs 2019; 79: 1419-1434 DOI: 10.1007/s40265-019-01173-2. (PMID: 31352605)
• 49 Greuter T, Hirano I, Dellon ES. Emerging therapies for eosinophilic esophagitis. J Allergy Clin Immunol 2020; 145: 38-45 DOI: 10.1016/j.jaci.2019.10.027. (PMID: 31705907)
• 50 Hirano I, Collins MH, Assouline-Dayan Y. et al. RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis. Gastroenterology 2019; 156: 592-603 DOI: 10.1053/j.gastro.2018.10.051. (PMID: 30395812)
• 51 Dellon ES, Collins MH, Rothenberg ME. et al. Long-Term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic Esophagitis. Clin Gastroenterol Hepatol 2020; DOI: 10.1016/j.cgh.2020.03.036.
• 52 Hirano I, Dellon ES, Hamilton JD. et al. Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis. Gastroenterology 2020; 158: 111-122
• 53 Sastre J, Dávila I. Dupilumab: A New Paradigm for the Treatment of Allergic Diseases. J Investig Allergol Clin Immunol 2018; 28: 139-150 DOI: 10.18176/jiaci.0254. (PMID: 29939132)
• 54 Kuang FL, Legrand F, Makiya M. et al. Benralizumab for PDGFRA-negative hypereosinophilic syndrome. N Engl J Med 2019; 380: 1336-1346 DOI: 10.1056/NEJMoa1812185. (PMID: 30943337)
• 55 Greuter T, Straumann A. Medical algorithm: Diagnosis and treatment of eosinophilic esophagitis in adults. Allergy 2020; 75: 727-730 DOI: 10.1111/all.14112. (PMID: 31714997)